What is it?
 Speech:  
HONcode sites All Web sites HONselect News Conferences Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2008: N O S A J J M A M F J
2007: D

 

     Posting date: 02-Dec-2008

 
Other news for:
Brain
Hormones
Occupational Health
Sleep Disorders
Travel
Resources from HONselect
Drug Effective for Temporary Sleep Disruptions
Trials of tasimelteon show it could aid shift workers, people affected by jet leg

By Robert Preidt

TUESDAY, Dec. 2 (HealthDay News) -- The experimental drug tasimelteon helps treat temporary insomnia caused by jet lag or night shifts, according to the results of two new clinical trials.

The phase II study included 39 people randomly assigned to receive either 10 milligrams, 20 mg, 50 mg or 100 mg of tasimelteon, or a placebo. They were monitored for seven nights -- three at baseline, three after a five-hour advance of sleep-wake schedule with treatment before sleep, and one night after treatment.

The phase III trial included 411 people who had transient insomnia induced in a sleep clinic by a five-hour advance of their sleep-wake cycle. They received either 20 mg, 50 mg, or 100 mg of tasimelteon, or a placebo, 30 minutes before bedtime.

The patients in the trials were monitored to determine their sleep efficiency (amount of actual sleep during their time in bed) and sleep latency (time it took them to fall asleep). Compared to placebo, tasimelteon (a melatonin analogue) improved sleep efficiency and reduced sleep latency, according to the researchers. They also found that patients taking tasimelteon showed an earlier shift in plasma melatonin rhythm.

The findings were published online and in an upcoming print issue of the The Lancet .

"The development of melatonin analogues, which specifically target melatonin receptors, will also help us to understand more about the role of the hormone melatonin in the regulation of sleep," the American and Australian researchers said in a journal news release.

"By simultaneously improving sleep latency and sleep maintenance with a shift in circadian rhythms, tasimelteon has the potential for the treatment of patients with transient insomnia associated with circadian rhythm sleep disorders, including people affected by jet leg, or those who work at night, and early-riser workers," the study authors concluded.

More information

The U.S. National Sleep Foundation has more about shift work .

SOURCE: The Lancet , news release, Dec. 1, 2008

Copyright © 2008 ScoutNews, LLC . All rights reserved.URL:http://www.healthscout.com/template.asp?id=621861

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img Contact img MediaCorner img HONewsletter img Ethical policy img Site map
HON Foundation is an NGO in Special Consultative Status with the Economic and Social Council of the United Nations
/News/HSN/621861.html
Last modified:  Dec 2 2008 © HON 2008